Intervention News

WASHINGTON — Contradicting previous research, in a large trial of patients referred for PCI after acute MI, colchicine did not improve CV outcomes compared with placebo, according to the CLEAR SYNERGY (OASIS-9) trial presented at TCT 2024.

WASHINGTON — In patients with moderate aortic stenosis and HF with reduced ejection fraction, transcatheter aortic valve replacement did not improve clinical outcomes but may raise quality of life vs. clinical surveillance, data show.

WASHINGTON — Among patients with asymptomatic severe aortic stenosis and myocardial fibrosis, transcatheter or surgical aortic valve replacement did not improve outcomes compared with guideline-directed conservative management.

WASHINGTON — Among patients with asymptomatic severe aortic stenosis, those who had transcatheter aortic valve replacement had better CV outcomes compared with those who had routine clinical surveillance, according to results of the EARLY TAVR trial.

The FDA has granted premarket approval to the Neuroguard IEP System, a novel stenting system intended to ease the process for individuals with stroke, according to the manufacturer.

The Society for Cardiovascular Angiography and Interventions has released a consensus statement on how catheterization laboratories should manage the technical aspects of PCI for patients with STEMI.

In this Healio video exclusive, Sana M. Al-Khatib, MD, professor of medicine at Duke University School of Medicine, discusses barriers to developing cardiovascular digital health solutions for women.

In August, the FDA approved a novel miniaturized cardiac stent for infants and small children with coarctation of the aorta or pulmonary artery stenosis and can be expanded as they grew.

Texas Children’s Hospital was named the top hospital for pediatric cardiology and heart surgery in the 2024 to 2025 rankings by U.S. News & World Report for the eighth year in a row.

The American Heart Association Scientific Sessions will be held in-person only in Chicago from Nov. 16 to 18 and will feature eight late-breaking science sessions during the 3-day meeting.